Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial
Vianney Tricou(Takeda (Switzerland)), Derek Wallace(Takeda (France))
Cited by 208
Related Papers
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents
|New England Journal of Medicine|2019|378